News Release



Japan Credit Rating Agency, Ltd.

23-S-0122 January 19, 2024

Japan Credit Rating Agency, Ltd. (JCR) announces the following credit rating.

<Asset Securitization Products> Medical Treatment Fees Receivable ABL Program (R Hospital in Hokkaido)

<Affirmation>

ABL Program: J-1

Rationale

R Hospital in Hokkaido securitizes two months of its medical treatment fees receivable from Health Insurance Claims Review & Reimbursement Services and The Federation of National Health Insurance Associations. Having reviewed the rating on this ABL program following program renewal, JCR evaluates that the subordination level is satisfactory so that certainty of principal repayment and interest payment as stipulated can be maintained at "J-1" level. There are no concerns about capabilities of parties to the structure to carry out their administrative duties. JCR evaluated the rating on this ABL program to be affirmed at "J-1," taking into account the above as a whole.

Riho Saiki, Yudai Matsumoto

Rating

<Affirmation>

Instrument Name: Medical Treatment Fees Receivable ABL Program (R Hospital in Hokkaido)

Maximum: JPY 300 million

Program Establishment Date: September 28, 2018

Credit Enhancement & Liquidity Facility: Senior-subordinated structure

Program Subordination Ratio: 20.00% (Subordination Ratio = Subordination Amount / Total Amount of

Receivables, rounded to two decimal places)

Coupon Type: Fixed

Redemption Method: Bullet Redemption

Rating: J-1

<Information on Outline of Issue>

ABL Execution Amount*: JPY 50,510,865 ABL Execution Date*: January 22, 2024

Final Maturity Dates*: May 27 and June 26, 2024

Disclosure Requirements for Securitization Transaction Ratings with respect to Basel II have been met.

<Information on Structure and Stakeholders>
Originator: R Hospital in Hokkaido (medium scale)

SPC: Progress Funding Corporation Arranger: North Pacific Bank, Ltd.

<Information on Underlying Assets>

Outline of Underlying Assets: Medical treatment fees receivable under health insurance held by R Hospital against Health Insurance Claims Review & Reimbursement Services and The Federation of National Health Insurance Associations

*This instrument is an ABL program in which an asset-backed loan (ABL) is executed repeatedly and continually under the same scheme, and ABL Execution Amount, etc. are the same as the conditions specified when JCR assigned the rating.



Rating Assignment Date: January 18, 2024

The assumptions for the credit ratings and the definitions of the rating symbols are published as "Types of Credit Ratings and Definitions of Rating Symbols" (January 6, 2014) in Information about JCR Ratings on JCR's website (https://www.jcr.co.jp/en/).

Outline of the rating methodology is shown as "Medical Remuneration Receivables" (July 3, 2017) in Information about JCR Ratings on JCR's website (https://www.jcr.co.jp/en/). Rating methodologies for other ancillary points such as eligible deposit accounts and bankruptcy remoteness are also shown within the same page.

The rating stakeholder participated in the rating process of the aforementioned credit ratings.

Japan Credit Rating Agency, Ltd.

Jiji Press Building, 5-15-8 Ginza, Chuo-ku, Tokyo 104-0061, Japan Tel. +81 3 3544 7013, Fax. +81 3 3544 7026

Information herein has been obtained by JCR from the issuers and other sources believed to be accurate and reliable. However, because of the possibility of human or mechanical error as well as other factors, JCR makes no representation or warranty, express or implied, as to accuracy, results, adequacy, timeliness, completeness or merchantability, or fitness for any particular purpose, with respect to any such information, and is not responsible for any errors or omissions, or for results obtained from the use of such information. Under no circumstances will JCR be liable for any special, indirect, incidental or consequential damages of any kind caused by the use of any such information including but not little to, lost opportunity or lost money, whether in contract, tort, strict liability or otherwise, and whether such damages are foreseeable. DrR's ratings and credit assessments are statements of JCR's current and comprehensive opinion regarding redemption possibility, etc. of financial obligations assumed by the issuers or financial products, and not statements of opinion regarding any risk other than credit risk, such as market liquidity risk or price fluctuation risk. JCR's ratings and credit assessments are statements of polinion, and not statements of fact as to credit risk decisions or recommendations regarding decisions to purchase, sell or hold any securities such as individual bonds or commercial paper. The ratings and credit assessments may be changed, suspended or withdrawn as a result of changes in or unavailability of information as well as other factors. JCR receives a rating fee paid by issuers for conducting rating services in principle. JCR retains all rights pertaining to this document, including JCR's rating data. Any reproduction, adaptation, alteration, etc. of this document, including such rating data, is prohibited, whether or not wholly or partly, without prior consent of JCR.

JCR is registered as a "Nationally Recognized Statistical Rating Organization" with the U.S. Securities and Exchange Commission with respect to the following four classes. (1) Financial institutions, brokers and dealers, (2) Insurance Companies, (3) Corporate Issuers, (4) Issuers of government securities, municipal securities and foreign government securities.

JCR publishes its press releases regarding the rating actions both in Japanese and in English on the same day. In case that it takes time to translate rating rationale, JCR may publicize the summary version, which will be replaced by the full translated version within three business days. (Regarding Structured Finance products, JCR only publicize the summary version in English.)